[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"obese-patients\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:obese-patients":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,45,76,109,133,154,178,227,259,285,311,338,362],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100593648","phase-2-study-to-evaluate-the-efficacy-and-safety-of-kds2010-in-overweight-or-obese-patients-100593648",false,"NCT07009171","Study to Evaluate the Efficacy and Safety of KDS2010 in Overweight or Obese Patients","A Randomized, Double-blind, Placebo-controlled, Dose Finding, Phase 2a Clinical Trial to Evaluate the Efficacy and Safety of KDS2010 in Overweight or Obese Patients","Inclusion Criteria:\n\n* Adult males and females aged 18 years or older (or the legal age of adulthood in the respective country) as of the date of written consent\n* Subjects with BMI ≥30 kg\u002Fm² or BMI ≥27 kg\u002Fm² with at least one weight-related comorbidity (hypertension, dyslipidemia, cardiovascular disease, obstructive sleep apnea) at screening and baseline\n\n  * Hypertension: under treatment or have Systolic Blood Pressure (SBP) ≥130 mmHg or Diastolic Blood Pressure (DBP) ≥80 mmHg\n  * Dyslipidemia: under treatment or LDL \\> 160 mg\u002FdL or TG \\> 200 mg\u002FdL or HDL \\\u003C 40 mg\u002FdL\n  * Cardiovascular diseases (e.g., ischemic cardiovascular disease, NYHA Class I to III heart failure, Peripheral vascular disease (PVD), Abdominal aortic aneurysm (AAA), etc.)\n  * Obstructive sleep apnoea\n* Subjects who have documented a 500 kcal reduction\u002Fday in calorie intake and ≥150 minutes of physical activity\u002Fweek for ≥50% of the time during the run-in period\n* Subjects who have voluntarily provided written consent to participate after being informed about this clinical trial\n\nExclusion Criteria:\n\n* Subjects with a weight change of 5% or more within 12 weeks before screening\n* Subjects with less than 80% or more than 120% compliance during the Run-in period\n* Subjects with obesity due to secondary causes (neurological disorders, endocrine disorders, genetic disorders, congenital disorders, etc.)\n* Subjects with following medical history,\n\n  * Type 1 or Type 2 diabetes\n  * History of bariatric\u002Fmetabolic surgery (e.g., adjustable gastric banding, intragastric balloon insertion, sleeve gastrectomy, Roux-en-Y gastric bypass, biliopancreatic diversion, duodenal switch) or planning to undergo such surgery during the study period\n  * Heart failure classified as NYHA class IV\n  * Subjects with a medical history of malignant tumors within 5 years prior to screening (however, subjects with successfully treated basal cell carcinoma, squamous cell carcinoma of the skin, thyroid cancer, or other carcinoma in situ, with no recurrence for more than 3 years, may be enrolled at the investigator's discretion)\n  * Subjects with a medical history of hypersensitivity to MAO inhibitors\n  * Subjects with a medical history of cerebrovascular disease (e.g., transient ischemic attack, stroke) within 12 weeks prior to baseline, or those hospitalized for unstable angina or congestive heart failure\n  * Subjects with a history of depressive disorders or psychiatric disorders (e.g., schizophrenia, bipolar disorder, anxiety disorder) within 2 years prior to screening\n* Subjects with a history of the following drug administration,\n\n  \\-- Anti-obesity agents or weight-loss medications (including dietary supplements and herbal medicine) within 12 weeks before screening\n  * Corticosteroids administered for 2 consecutive weeks or more within 12 weeks before screening (however, topical preparations, including inhalants, are allowed)\n  * Treatment for hyperthyroidism or hypothyroidism at the time of screening (subjects on a stable dose and regimen for at least 12 weeks may be enrolled at the investigator's discretion)\n  * MAO inhibitors within 2 weeks before baseline\n  * Opioid medications (e.g., pethidine, Tramadol, Tapentadol) within 2 weeks before baseline\n  * Serotonergic drugs within 2 weeks before baseline,\n\n    * Selective Serotonin Reuptake Inhibitors (SSRI), ② Serotonin-Norepinephrine Reuptake Inhibitors (SNRI),\n\n      * Tricyclic or Tetracyclic antidepressant, ④ Triazolopyridine antidepressant, ⑤ Selective serotonin (5-HT1) agonists (Sumatriptan, etc.), (However, amitriptyline ≤50 mg\u002Fday, trazodone ≤100 mg\u002Fday, citalopram ≤20 mg\u002Fday, sertraline ≤100 mg\u002Fday, paroxetine ≤30 mg\u002Fday are allowed; long half-life serotonergic drugs (e.g., fluoxetine) require at least a 5-week wash out period before enrollment),\n  * Lithium, Bupropion, Lamotrigine, Ritonavir, Cyclobenzaprine, or St. John's wort within 2 weeks before baseline\n  * Hypertension crisis-inducing drugs (e.g., oxymetazoline, phentermine, phenylephrine) within 2 weeks before baseline\n  * Sympathomimetic agents (e.g., ephedrine, methylphenidate, amphetamine, methamphetamine, lisdexamfetamine) at the time of screening\n  * Dextromethorphan at the time of screening\n* Subjects who meet following criteria based on the tests conducted at Screening\n\n  * Glycated hemoglobin (HbA1c) ≥6.5%\n  * Hepatic impairment (Child-pugh class C)\n  * AST or ALT \\> 2.5 X ULN\n  * Total bilirubin \\>1.5 X ULN (however, \\>3.0 mg\u002FdL is acceptable in cases of Gilbert syndrome)\n  * Severe renal impairment (eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m² calculated using the MDRD formula\\*),\n\n    \\* eGFR = 175 X (Serum creatinine)-1.154 X (Age)-0.203 X (0.742 (for females)) X (1.212 (for African Americans))\n  * TSH \\>6.0 mIU\u002FL or \\\u003C0.4 mIU\u002FL,\n* Subjects with a lifetime history of suicide attempts\n* Subjects with a PHQ-9 score of 10 or higher at screening\n* Subjects who answer affirmatively to item 4 or 5 on the C-SSRS at screening\n* Pregnant or breastfeeding women\n* Females of childbearing potential and males who do not agree to use adequate contraception# until at least 2 weeks after the last dose of the IP or who plan to conceive during the study period,\n\n  * Adequate contraception is defined as double contraception using both barrier methods (male condom or female condom) and one of the contraceptive methods ①-③.\n\n    * Hormonal contraceptive (oral, injectable, implantable, etc.), ② Implantation of Intrauterine device (IUD) or intrauterine system (IUS), ③ Sterilization procedures or surgeries (bilateral tubal ligation, hysterectomy, vasectomy), ④ Complete abstinence: absolute abstinence is accepted if, in the investigator's judgment, the subject's age, occupation, lifestyle, or sexual orientation ensure compliance with contraception. However, periodic abstinence (calendar method, ovulation method, symptothermal method, etc.) withdrawal, and coitus interruptus are not considered adequate contraceptive methods.,\n* Subjects who have participated in another clinical trial and received an investigational drug or device within 4 weeks prior to screening\n* Other reasons (such as a medical history of alcohol or substance abuse) that the investigator deems the subject unsuitable for participation in this clinical trial","ALL","18 Years",{"count":19,"type":20},75,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This is a randomized, double-blind, placebo-controlled, dose-finding, Phase 2a study designed to evaluate the safety and efficacy of KDS2010 in overweight or obese patients. Based on preliminary efficacy observed in the Phase 1 study, this clinical trial is being conducted in Korea.\n\nAfter a minimum 2-week run-in period, subjects who meet the inclusion and exclusion criteria will be randomized to the treatment group or placebo group at a 2:1 ratio in each stage.\n\nSubjects will receive the investigational product for 12 weeks following randomization. The study will be conducted in three stages.\n\nApproximately 75 subjects will be enrolled, with 6 subjects in the KDS2010 120 mg group and 3 subjects in the placebo group in Stage 1, 22 subjects in the KDS2010 180 mg group and 11 subjects in the placebo group in Stage 2, and 22 subjects in the KDS2010 240 mg group and 11 subjects in the placebo group in Stage 3.\n\nThe primary objectives are to assess the efficacy and safety of KDS2010 in overweight or obese patients. Exploratory objectives include evaluating the proportion of subjects achieving a weight reduction of more than 25% from baseline at Week 12 and assessing changes in MAO-B specific activity and adiponectin levels.\n\nBased on nonclinical and Phase 1 clinical data, KDS2010 will be administered orally once daily at doses of 120 mg, 180 mg, and 240 mg throughout the study.",[26,27,28],"Overweight","Obesity","Obese Patients",[28,26,30,27,31],"KDS2010","MAO-B inhibitor","RECRUITING","2026-06-19",{"date":35,"type":36},"2026-06-24","ACTUAL",{"date":38,"type":36},"2025-07-29",{"date":40,"type":20},"2027-06-30",{"name":42,"class":43},"NeuroBiogen Co., Ltd","INDUSTRY",3,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":55,"conditions":56,"keywords":60,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":75},"100419979","access-to-kidney-transplant-of-obese-patients-beginning-dialysis-100419979","NCT04748770","Access to Kidney Transplant of Obese Patients Beginning Dialysis","Transplantob","Inclusion Criteria:\n\n* Age over 18 years old.\n* Patients with BMI≥30 kg\u002Fm2 (for study population) and 25≤BMI≤30 kg\u002Fm2(for control population) one month after dialysis initiation.\n* Patients agree with their data collection.\n\nExclusion Criteria:\n\n* Patients with bariatric surgery history.\n* Patients needed dialysis for graft dysfunction.\n* Data loss.",{"count":53,"type":20},100,"OBSERVATIONAL","Obesity is in constant increase all over the world and affects 35% of the global population according to the World Health Organisation. It is associated with other cardiovascular risk factors (particularly hypertension and diabetes) and with high morbi-mortality. It is also responsible for an increase of the risk of developing chronic kidney diseases (CKD). In fact, obese patients represent 25% of the dialysis population and Picardy is one of the most affected areas. However, their access to kidney transplant is still restricted and the reasons are not completely understood.",[57,28,58,59],"Kidney Transplant Access","Dialysis","Comorbidities",[61,62,63,64],"Kidney transplant access","obese patients","dialysis","comorbidities","2026-06-12",{"date":67,"type":36},"2026-06-15",{"date":69,"type":36},"2021-01-11",{"date":71,"type":20},"2026-06",{"name":73,"class":74},"Centre Hospitalier Universitaire, Amiens","OTHER",1,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":84,"sex":16,"minAge":17,"maxAge":85,"enrollmentInfo":86,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":87,"conditions":88,"keywords":92,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":75},"100622247","bariatric-surgery-and-gut-microbiota-changes-over-time-100622247","NCT07381140","Bariatric Surgery and Gut Microbiota Changes Over Time","Longitudinal Evaluation of Gut Microbiota and Fecal Metabolome Following Roux-en-Y Gastric Bypass: Clinical Implications and Identification of Predictive Biomarkers","RYGB-MICROGUT","Inclusion Criteria (RYGB Group):\n\n* Age between 18 and 65 years.\n* Adults with a body mass index (BMI) ≥ 35 kg\u002Fm² with related comorbidities, or BMI ≥ 40 kg\u002Fm², who are candidates for Roux-en-Y gastric bypass (RYGB) surgery only.\n\nExclusion Criteria (RYGB Group):\n\n* Treatment with antibiotics within the last 3 weeks, or probiotics\u002Fprebiotics within the last 4-6 weeks, or systemic corticosteroids within the 8 weeks prior to baseline (T0).\n* Participation in dietary regimens or calorie restriction programs in the weeks prior to enrollment.\n* Chronic inflammatory bowel diseases (e.g., Crohn's disease, ulcerative colitis), ongoing enteric infections, or active neoplasms.\n* Previous organ transplant or ongoing systemic immunosuppressive therapy.\n* Pregnancy or breastfeeding.\n* Previous major gastrointestinal surgery.\n* Chronic alcohol consumption above moderate levels or substance use disorder.\n\nInclusion Criteria (Obese Control Group):\n\n* Age between 18 and 65 years.\n* Adults with BMI ≥ 30 kg\u002Fm² who are candidates for structured dietary treatment.\n\nInclusion Criteria (Healthy Control Group):\n\n* Age between 18 and 65 years.\n* Normal weight (BMI between 18.5 and 24.9 kg\u002Fm²).\n* Normal metabolic function: fasting glucose below threshold, normal ALT\u002FAST, no diagnosis of diabetes or metabolic syndrome.\n* No chronic gastrointestinal diseases or conditions that could alter the gut microbiota.\n\nExclusion Criteria (Obese Control and Healthy Control Group):\n\n* Use of antibiotics within the last 3 weeks or probiotics\u002Fprebiotics within the last 4-6 weeks.\n* Recent gastrointestinal surgery.\n* Pregnancy or breastfeeding.\n* Extreme diets or recent dietary changes.\n* Recent international travel that could have affected the gut microbiota.\n* Medications known to influence the gut microbiota (e.g., PPIs, metformin, steroids).\n* Active smoking or excessive alcohol consumption.\n* Significant gastrointestinal symptoms (chronic diarrhea or constipation).",true,"65 Years",{"count":53,"type":20},"The goal of this observational study is to learn how bariatric surgery affects gut bacteria and gut-related metabolic products over time in adults with obesity. The study includes adults aged 18 to 65 years who are undergoing Roux-en-Y gastric bypass (RYGB) surgery, as well as adults with obesity treated with diet alone and healthy normal-weight adults.\n\nThe main questions it aims to answer are:\n\nHow does bariatric surgery change the composition and diversity of gut bacteria over time? How are these changes related to weight loss and improvement of obesity-related health conditions?\n\nResearchers will compare people undergoing bariatric surgery with people with obesity treated with diet alone and with healthy normal-weight individuals to see if surgery leads to specific changes in gut bacteria and stool metabolites that are linked to better clinical outcomes.\n\nParticipants will:\n\nProvide stool samples at scheduled time points over 12 months Provide blood samples and undergo routine clinical assessments Take part in follow-up visits to monitor weight, metabolic health, and gastrointestinal symptoms",[28,89,90,91],"Obese Patients With Bariatric Surgery","Gut Microbiota","Healthy Participants",[93,94,95,96,97,98],"gut microbiota","stool metabolome","obesity","bariatric surgery","Roux-en-Y gastric bypass","Long-read sequencing","NOT_YET_RECRUITING","2026-02-03",{"date":102,"type":36},"2026-02-05",{"date":104,"type":20},"2026-04",{"date":106,"type":20},"2028-04",{"name":108,"class":74},"Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis",{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":4,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":16,"minAge":116,"maxAge":117,"enrollmentInfo":118,"targetDuration":4,"studyType":21,"phases":120,"briefSummary":122,"conditions":123,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":131,"locationsCount":75},"100623458","keto-tumor-a-study-on-brain-tumors-and-central-obesity-100623458","NCT07396896","KETO-TUMOR: a Study on Brain Tumors and Central Obesity","Single-arm, Open-label, Single-center, Non-profit Interventional Clinical Trial on the Effects of the Ketogenic Diet in Patients With Brain Tumors and Central Obesity","Inclusion Criteria:\n\n1. Diagnosis of hypothalamic-chiasmatic tumour according to the WHO 2021 classification\n2. Diagnosis of hypothalamic obesity: after 5 years of age, BMI \\>97th percentile in the WHO 2007 curves\n3. Males and females aged between 7 and 30 years\n4. Performance status: Lansky score \\> 40 for patients aged \\\u003C 18 years and Karnofsky score \\> 40 for patients aged between 18 and 30 years\n5. Signature of informed consent to participate in the study\n6. Signature of consent by the minor patient to participate in the study (7-13 years and 14-17 years).\n\nExclusion Criteria:\n\n1\\. Deficiencies of:\n\n* Primary carnitine\n* Carnitine palmitoyltransferase 2 (CPT 2)\n* Carnitine acylcarnitine translocase (CACT)\n* Beta-oxidation\n* Medium-chain acyl-CoA dehydrogenase (MCAD)\n* long-chain acyl-CoA dehydrogenase (LCAD)\n* short-chain acyl-CoA dehydrogenase (SCAD)\n* porphyria\n* pyruvate carboxylase\n* long-chain 3-hydroxyacyl-CoA dehydrogenase.","7 Years","30 Years",{"count":119,"type":20},30,[121],"NA","Hypothalamic-chiasmatic tumours account for 5-10% of CNS tumours in children and can compromise hypothalamic function, causing alterations in energy balance and weight gain. In inoperable cases, chemotherapy and radiotherapy are used; the latter, although the gold standard, is associated with significant neurocognitive and endocrine-metabolic side effects, proportional to the hypothalamic damage.\n\nThe ketogenic diet, used for decades in the treatment of drug-resistant childhood epilepsy, induces the use of ketone bodies as a source of energy for the brain and is effective in controlling seizures. Among the different variants, the modified Atkins diet was chosen in this study to promote better patient adherence.\n\nThis study aims to evaluate the effectiveness of the ketogenic diet (KD) in treating central obesity secondary to hypothalamic-chiasmatic tumours (gliomas, craniopharyngiomas, germ cell tumours, etc.), which often lead to excessive weight gain. This is refractory to drug therapy and lifestyle changes, such as low-calorie diets and exercise.",[28,124],"Hypothalamic Neoplasms","2026-02-02",{"date":127,"type":36},"2026-02-09",{"date":129,"type":36},"2025-05-08",{"date":106,"type":20},{"name":132,"class":74},"Meyer Children's Hospital IRCCS",{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":137,"acronym":138,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":140,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":142,"conditions":143,"keywords":4,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":4},"100609371","evaluation-of-anti-xa-activity-in-patients-with-severe-obesity-after-subcutaneous-injection-of-enoxaparin-for-antithrombotic-prophylaxis-at-two-different-sites-100609371","NCT07213713","Evaluation of Anti-Xa Activity in Patients With Severe Obesity After Subcutaneous Injection of Enoxaparin for Antithrombotic Prophylaxis at Two Different Sites.","EPOS","Inclusion Criteria:• age \\>18 years,\n\n* BMI \\>40 kg\u002Fm2\n* indication to primary or secondary thromboprophylaxis (Padua Score \\> 4), as clinical practice\n\nExclusion Criteria:• indication to full dose anticoagulant,\n\n* creatinine clearance \\\u003C30 mL\u002Fmin (based on Cockcroft-Gault equation using adjusted body weight),\n* pregnant women,\n* low platelet count (\\\u003C50.000\u002FmicroL or \\\u003C100.000\u002FmicroL plus additional risk factors for bleeding),\n* active bleeding,\n* active gastroduodenal ulcer,\n* severe bleeding diathesis,\n* recent\u002Fplanned\u002Femergency high bleeding-risk surgery\u002Fprocedure,\n* major trauma,\n* acute intracranial hemorrhage,\n* bleeding within the three months prior to admission,\n* known hypersensitivity to enoxaparin (e.g. pruritus, urticaria, anaphylactic\u002Fanaphylactoid reactions),\n* history of immune mediated heparin-induced thrombocytopenia (HIT),\n* severe uncontrolled hypertension,\n* diabetic or hemorrhagic retinopathy,\n* concurrent administration of subcutaneous drugs (i.e. insulin, GLP-1 receptor agonists, etc.).",{"count":141,"type":20},80,"To evaluate appropriateness of enoxaparin bioavailability at two different sites of subcutaneous administration (arms or abdomen) in primary or secondary prevention of thromboembolism in a population of patients with severe obesity",[144,28],"Venous Thromboembolism","2025-10-02",{"date":147,"type":36},"2025-10-09",{"date":149,"type":20},"2025-10-01",{"date":151,"type":20},"2027-10-01",{"name":153,"class":74},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":160,"eligibilityCriteria":161,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":162,"enrollmentInfo":163,"targetDuration":4,"studyType":21,"phases":165,"briefSummary":166,"conditions":167,"keywords":4,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":75},"100607752","intravenous-tranexamic-acid-100607752","NCT07192640","Intravenous Tranexamic Acid","PERIOPERATIVE USE OF INTRAVENOUS TRANEXAMIC ACID FOR HIGH BMI PATIENTS GOING THROUGH BARIATRIC SURGERIES","TXA","Inclusion Criteria:\n\n* High-risk patients, with obesity, BMI more than 45,\n* Patients with Preexisting cardiovascular condition, Hypertension, diabetes, or coagulation disorders, thyroid dysfunction and pulmonary disorders.\n\nExclusion Criteria:\n\n* patients with active thromboembolic disorders.\n* Patients with preexisting renal dysfunction,","60 Years",{"count":164,"type":20},128,[121],"Tranexamic acid is a promising option for minimizing blood loss in high-risk bariatric surgery patients, particularly in those with obesity, diabetes, and other comorbidities. When used appropriately, TXA can reduce the need for blood transfusions, maintain hemodynamic stability, and lower the incidence of complications related to blood loss.",[28,89,168],"Bleeding","2025-09-23",{"date":171,"type":36},"2025-09-25",{"date":173,"type":20},"2025-10-15",{"date":175,"type":20},"2026-03-30",{"name":177,"class":74},"Ain Shams University",{"id":179,"slug":180,"hasResults":11,"nctId":181,"briefTitle":182,"officialTitle":183,"acronym":4,"eligibilityCriteria":184,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":185,"enrollmentInfo":186,"targetDuration":4,"studyType":21,"phases":188,"briefSummary":189,"conditions":190,"keywords":199,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":219,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":225,"locationsCount":75},"100599458","non-opioid-anesthesia-based-on-thoracic-paravertebral-block-during-laparoscopic-sleeve-gastrectomy-100599458","NCT07084753","Non-opioid Anesthesia Based on Thoracic Paravertebral Block During Laparoscopic Sleeve Gastrectomy","Comparison of Opioid-based Anesthesia, Opioid-free Anesthesia Based on Intravenous Drugs and Opioid-free Anesthesia With Thoracic Paravertebral Block, in Patients Undergoing Laparoscopic Gastric Bypass Surgery for Obesity","Inclusion Criteria:\n\n-. patients with a prior history of treatment by a multidisciplinary obesity team scheduled for laparoscopic sleeve gastrectomy (LSG)\n\n* body mass index of 30 kg\u002Fm² or greater\n* patients classified as ASA status 2-3.\n\nExclusion Criteria:\n\n* allergies to the intended medications\n* patient refusal\n* uncontrolled psychiatric disorders\n* intracranial pathology\n* cerebrovascular damage\n* any factors impairing effective communication\n\nAdditional Exclusion Criteria:\n\n1. For patients receiving thoracic paravertebral block (TPVB):\n\n   \\- the presence of infection at the puncture site\n2. For the OFA group:\n\n   * 2nd or 3rd-degree atrioventricular block\n   * bradycardia with a heart rate below 50 beats per minute\n   * coronary artery disease,\n   * cardiomyopathy.","70 Years",{"count":187,"type":20},36,[121],"Regional anesthesia is a technique in which a local anesthetic is injected near a nerve or spinal cord to block sensation, motor stimulation, and pain. In this study, an ultrasound-guided paravertebral block will be used, with careful consideration of all positive and negative factors and possible complications. A thoracic paravertebral block is performed by inserting a needle into the intercostal spaces on the back, approximately 4 cm lateral to the spine. Many studies support excellent pain control with this technique, during and after surgery in thoracic and abdominal surgery. Investigators aim to achieve faster patient mobility after surgery, rapid recovery of bowel function, reduced nausea and vomiting, and maximum pain control. The use of opioids, which can additionally cause respiratory suppression and drowsiness, is avoided.\n\nAt any time in case of need to switch from laparoscopic to open surgery, equally adequate anesthesia and postoperative analgesia are ensured without the need to change the approach to the same. In this study, the basic scientific assumption (hypothesis) of the researchers is that non-opioid anesthesia with thoracic paravertebral block provides adequate pain control during and long-term after the surgical procedure, without the side effects of opioid anesthesia.\n\nThe main goal of the study is to determine which type of anesthesia results in the best pain control and most significantly reduces complications of anesthesia and surgery in overweight patients who are scheduled for laparoscopic longitudinal gastrectomy and partial\u002Ftotal gastrectomy.",[28,191,192,193,194,195,196,197,198],"Bariatric Surgical Pain","Bariatric Surgery (Sleeve Gastrectomy )","Non-Opioid Pain Management","PONV","Postoperative Analgesia","Postoperative Pain","Thoracic Paravertebral Block","Opioid Free Anesthesia",[200,62,96,201,202,203,204,205,206,207,208,209,210,211,212,213,193,194,214,215,216,217],"thoracic paravertebral block","sleeve gastrectomy","postoperative pain management","anesthesia recovery period","non-opioid anesthesia","recovery after bariatric surgery","TPVB","OFA based on thoracic paravertebral block","Visceral pain, Postoperative","Opioid based anesthesia","Opioid free anesthesia","OBA","OFA","Recovery Period, Anesthesia","Postoperative analgesia","Postoperative pain","Bariatric Surgery, Pain","Opioid free anesthesia, dexmedetomidine, ketamine, lidocaine","2025-07-17",{"date":220,"type":36},"2025-07-24",{"date":222,"type":20},"2025-07-30",{"date":224,"type":20},"2025-10",{"name":226,"class":74},"IVO JURISIC",{"id":228,"slug":229,"hasResults":11,"nctId":230,"briefTitle":231,"officialTitle":232,"acronym":4,"eligibilityCriteria":233,"healthyVolunteers":11,"sex":16,"minAge":234,"maxAge":235,"enrollmentInfo":236,"targetDuration":4,"studyType":21,"phases":238,"briefSummary":239,"conditions":240,"keywords":245,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":256,"locationsCount":75},"100573464","nonendoscopic-screening-for-barretts-esophagus-in-veterans-without-chronic-reflux-100573464","NCT06746623","Nonendoscopic Screening for Barrett's Esophagus in Veterans Without Chronic Reflux","Nonendoscopic Screening for Barrett's Esophagus and Esophageal Cancer in At-Risk Veterans Without History of Chronic Gastroesophageal Reflux","Inclusion Criteria:\n\n* Patients without history of chronic GERD who meet criteria for upper endoscopic screening for BE will be accrued35.\n\n  1. Adults \\> 40 and \\\u003C 85 years old who have no prior EGD and can provide informed consent\n  2. Absence of chronic GERD symptoms (absence of weekly heartburn or regurgitation, not on medications for GERD), and are:\n\n     a. Meet ACG\u002FAGA Clinical Guideline criteria for BE screening. Eligible subjects will have at least three additional risk factors for BE (white race, obesity defined as BMI \\> 30, male gender, current smoker or smoking history \\> 10 pack years, family history of Barrett's esophagus or EAC central obesity (waist size \\> 35 inches for women and \\> 40 inches for men), white race, male sex, confirmed history of BE\u002FEAC in at least two family members, with one a first degree relative).\n  3. No known coagulopathy, no known esophageal varices, not on chronic anticoagulation therapy, and have:\n  4. No significant dysphagia or odynophagia\n\nExclusion Criteria:\n\n* Exclusion Criteria\n\n  1. History of prior EGD procedure in past ten years\n  2. Inability to provide written informed consent\n  3. History of weekly or more frequent heartburn or regurgitation for five or more years\n  4. On anti-coagulant drug(s) that cannot be temporarily discontinued or coagulopathy with INR \\> 1.5\n  5. Known history of esophageal varices or esophageal stricture\n  6. Any contraindication, as deemed in Investigator's medical judgment, to undergoing the EsoCheck procedure, undergoing the EGD procedure, and\u002For having biopsies taken, including but not limited to due to comorbidities such as coagulopathy or a known history of esophageal diverticula, esophageal fistula and\u002For esophageal ulceration\n  7. History of difficulty swallowing (dysphagia) or painful swallowing (odynophagia), including swallowing pills\n  8. Oropharyngeal tumor\n  9. History of esophageal or gastric surgery, with exception on uncomplicated recent surgical fundoplication procedure with documented normal acid exposure time (AET) percent (AET \\\u003C4%)\n  10. History of myocardial infarction or cerebrovascular accident within past 6 months","40 Years","85 Years",{"count":237,"type":20},400,[121],"The veteran population is at increased risk for EAC and its precursor lesion, Barrett's esophagus (BE), due to increased prevalence of disease risk factors compared to the general population. BE is traditionally diagnosed only when patients undergo endoscopy with biopsies. However, due to the high cost of endoscopy and the lack of studies proving efficacy of screening, endoscopy to screen for BE is not routinely recommended. A simpler screening procedure similar to a pap smear would be an ideal way to sample the esophageal tissue for cancer and its precursor condition, BE. This study proposes a non-endoscopic detection method administered in outpatient offices which would increase subsequent endoscopic detection of BE. The study team will be enrolling veterans who do not have history of gastroesophageal reflux but have multiple risk factors for esophageal adenocarcinoma.",[28,241,242,243,244],"Tobacco Use","Veterans","Family History of Esophageal Cancer","Barrett Esophagus",[246,247,248],"Non-endoscopic screening","esophagus","Barrett","2025-06-03",{"date":251,"type":36},"2025-06-05",{"date":253,"type":36},"2025-04-11",{"date":255,"type":20},"2028-12-31",{"name":257,"class":258},"Louis Stokes VA Medical Center","FED",{"id":260,"slug":261,"hasResults":11,"nctId":262,"briefTitle":263,"officialTitle":264,"acronym":4,"eligibilityCriteria":265,"healthyVolunteers":11,"sex":16,"minAge":266,"maxAge":267,"enrollmentInfo":268,"targetDuration":4,"studyType":21,"phases":270,"briefSummary":271,"conditions":272,"keywords":273,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":276,"lastUpdatePostDateStruct":277,"startDateStruct":279,"completionDateStruct":281,"leadSponsor":283,"locationsCount":4},"100592605","impact-of-thoracic-duct-ligation-on-postoperative-weight-reduction-in-obese-patients-receiving-minimally-invasive-lung-surgery-a-clinical-investigation-100592605","NCT06995599","Impact of Thoracic Duct Ligation on Postoperative Weight Reduction in Obese Patients Receiving Minimally Invasive Lung Surgery: A Clinical Investigation","Thoracic Duct Ligation and Postoperative Weight Loss in Obese Patients Undergoing Minimally Invasive Lung Surgery: A Pilot Exploratory Clinical Study","Inclusion Criteria:\n\n1. Age \\& Gender: Individuals aged 18-75 years, regardless of gender.\n2. Clinical Profile:Diagnosed with early-stage lung cancer (stage IA1-IB) and obesity (BMI ≥28 kg\u002Fm²).\n3. Scheduled to undergo video-assisted thoracoscopic surgery (VATS) for right-sided lung cancer resection at our institution between October 2024 and October 2026.\n4. Surgical Eligibility: Approved for surgery following multidisciplinary team (MDT) assessment.\n5. Treatment Plan: No requirement for adjuvant therapy post-lung resection.\n6. Preoperative Evaluation:Completed standard preoperative workup, including:\n7. Chest CT、Brain CT\u002FMRI、Abdominal ultrasound OR PET-CT to rule out distant metastasis.\n8. Informed Consent: Willing and able to comply with study requirements, with written informed consent provided.\n\nExclusion Criteria:\n\n1. Concurrent Thoracic Infections: Patients with active intrathoracic infectious diseases (e.g., inflammatory conditions, tuberculosis).\n2. Refusal of Novel Technique: Patients unwilling to undergo intraoperative thoracic duct ligation.\n3. Clinically Unstable Comorbidities: Severe, unstable cardiovascular, renal, or respiratory disorders.\n4. Prior Bariatric Surgery: History of weight-loss surgery (e.g., gastric bypass, sleeve gastrectomy).\n5. Recent Trial Participation: Enrollment in other clinical trials within 30 days prior to screening.\n6. Investigator Discretion: Other conditions deemed by the investigator to contraindicate participation.","18 Days","75 Days",{"count":269,"type":20},16,[121],"This clinical trial aims to investigate whether thoracic duct ligation (TDL) can improve obesity and lipid metabolism. The primary questions it seeks to answer are:\n\nWhether thoracic duct ligation can improve BMI and lipid metabolism in obese patients.\n\nThe safety and feasibility of thoracic duct ligation as a treatment for obesity.",[28],[27,274,275],"therapy","Metabolic Effects of Thoracic Duct Ligation","2025-05-21",{"date":278,"type":36},"2025-05-29",{"date":280,"type":20},"2025-06-01",{"date":282,"type":20},"2027-12-31",{"name":284,"class":74},"Yongxin Zhou",{"id":286,"slug":287,"hasResults":11,"nctId":288,"briefTitle":289,"officialTitle":290,"acronym":4,"eligibilityCriteria":291,"healthyVolunteers":84,"sex":292,"minAge":293,"maxAge":294,"enrollmentInfo":295,"targetDuration":4,"studyType":21,"phases":297,"briefSummary":298,"conditions":299,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":302,"lastUpdatePostDateStruct":303,"startDateStruct":305,"completionDateStruct":307,"leadSponsor":309,"locationsCount":75},"100587485","a-study-on-application-of-adjustable-headrest-in-painless-curettage-surgery-for-overweight-and-obese-patients-100587485","NCT06929000","A Study on Application of Adjustable Headrest in Painless Curettage Surgery for Overweight and Obese Patients","A Study on Application of Adjustable Headrest in Painless Curettage Surgery for Overweight and Obese Patients: a Randomized Controlled Trial","Inclusion Criteria:\n\n* patients who choose to have painless surgical abortion\n* Body mass index greater than 24\n* the American Society of Anesthesiologists (ASA) physical status ranked I-II\n* competent to provide informed consent\n\nExclusion Criteria:\n\n* Abnormal lung function or respiratory system diseases\n* Airway obstruction or respiratory malformation\n* cervical spondylosis\n* psychiatric disorders","FEMALE","20 Years","50 Years",{"count":296,"type":20},300,[121],"The aim of this study is to observe the effect of adjustable headrests on ventilation function in overweight and obese patients through clinical experiments, and to explore the impact on the incidence of hypoxemia during painless curettage in overweight and obese patients.\n\nParticipants will be randomly allocated to three groups: the supine head-straight position group(Group A), the supine head-lateral position group(Group B), and the adjustable headrest group(Group C). These three groups of patients underwent painless curettage surgery in the daytime operating room and the occurrence of hypoxemia will be observed.",[300,301,28],"Adjustable Headrests","Ventilation Function","2025-04-08",{"date":304,"type":36},"2025-04-15",{"date":306,"type":36},"2025-02-25",{"date":308,"type":20},"2026-09-22",{"name":310,"class":74},"Maternal and Child Health Hospital of Hubei Province",{"id":312,"slug":313,"hasResults":11,"nctId":314,"briefTitle":315,"officialTitle":316,"acronym":317,"eligibilityCriteria":318,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":319,"targetDuration":4,"studyType":21,"phases":321,"briefSummary":322,"conditions":323,"keywords":324,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":329,"lastUpdatePostDateStruct":330,"startDateStruct":332,"completionDateStruct":334,"leadSponsor":336,"locationsCount":75},"100583062","telerehabilitation-as-follow-up-for-obesity-100583062","NCT06871436","Telerehabilitation as Follow-up for Obesity","Telerehabilitation as a Follow-up Modality for Obese People After Returning Home Following Hospitalization","OPaCTe","Inclusion Criteria:\n\n* Adult (\\> 18 years old)\n* BMI \\> 35 or 30 Kg\u002Fm2 in case of concomitant comorbidity\n* Authorization to practice physical activity for participants over 30 years old by means of a cardiac assessment and an ECG less than 6 months old carried out by a cardiologist. As part of the COBD treatment, the ECG is either: integrated into the patient file before hospitalization if the patient has seen his cardiologist staff. Either the ECG is provided in the file or carried out and analyzed by the center's cardiologist (Dr Rouffaud). The latter then authorizes or not the practice of PA.\n* Complete 3-week stay in an obesity center\n* Availability of equipment suitable for telerehabilitation at home\n* Having given informed consent for participation in the study\n\nExclusion Criteria:\n\n* Medical contraindication to PA practice defined by a doctor\n* Participation in a concomitant research protocol\n* For women of childbearing age, they will be informed that in the event of pregnancy occurring during participation in the research, they will not be able to continue the protocol and will withdraw from the research\n* Refusal to participate in the research protocol\n* Patient on weekday stay (\\\u003C 3 weeks)\n* Psychiatric\u002Fpsychological disorder limiting the expression of consent\n* Persons under legal protection or unable to express their consent\n* Inability to participate in any of the 18 Telerehabilitation sessions",{"count":320,"type":20},138,[121],"The goal of this experimental study is to observed the impact of telerehabilitation modalities in obese patient after a hospitalization on physical intensity at home (MVPA). The secondary aim is to observe the evolution of clinical parameters such as anthropometric data, adherence and psychological state.",[28],[325,27,326,327,328],"Telerehabilitation","Adults","Physical Exercise","Mindsets","2025-03-05",{"date":331,"type":36},"2025-03-12",{"date":333,"type":20},"2025-04-07",{"date":335,"type":20},"2026-08-07",{"name":337,"class":74},"Centre de l'Obesite Bernard Descottes",{"id":339,"slug":340,"hasResults":11,"nctId":341,"briefTitle":342,"officialTitle":343,"acronym":4,"eligibilityCriteria":344,"healthyVolunteers":84,"sex":16,"minAge":17,"maxAge":345,"enrollmentInfo":346,"targetDuration":4,"studyType":21,"phases":348,"briefSummary":349,"conditions":350,"keywords":351,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":353,"lastUpdatePostDateStruct":354,"startDateStruct":356,"completionDateStruct":358,"leadSponsor":360,"locationsCount":75},"100567850","intragastric-balloon-for-treatment-of-overweight-and-obesity-which-is-the-best-filling-volume-100567850","NCT06673550","Intragastric Balloon for Treatment of Overweight and Obesity: Which is the Best Filling Volume?","Fluid-filled Intragastric Balloon's Filling Volume At 500, 600, or 700 Ml for Treatment of Overweight and Obesity: Which is the Magic Number? a Single Centre Randomized Study","Inclusion Criteria:\n\n* age \\> 18 years, obesity grade I-III, or overweight with at least one obesity-related comorbidity\n\nExclusion Criteria:\n\n* history of bariatric surgery or endoscopy, allergies to methylene blue, childbearing or not willing to participate or comply with follow-up","80 Years",{"count":347,"type":20},156,[121],"TITLE: Randomized study conducted in a single center, with the aim of comparing the three main filling volumes of the intragastric balloon in overweight or obese patients (BMI \\>27 and \\\u003C60 kg\u002Fm2).\n\nOBJECTIVE: To establish the efficacy and safety of the intragastric balloon inflated to different volumes in patients who are candidates for balloon placement for overweight or obesity. To date there is no well-defined filling volume and each Endoscopist inflates the balloon to a random volume between 500 and 700 ml according to the experience acquired, but without a clear rationale.\n\nDESIGN: All overweight or obese patients with an indication for intragastric balloon placement will be preliminarily examined by a multidisciplinary team composed of a gastroeterologist, surgeon, nutritionist, psychologist, radiologist and endocrinologist.\n\nBefore each bariatric procedure, patients will undergo a psychometric and nutritional evaluation in order to identify any psychopathological conditions that contraindicate the operation.\n\nThe enrolled patients will be randomly divided to be candidates for balloon placement:\n\n* 1\u002F3 of patients will undergo treatment with an intragastric balloon inflated with 500 ml of saline solution and methylene blue, a space-occupying technique, which will be left in place for 1 year;\n* 1\u002F3 of patients will undergo treatment with an intragastric balloon inflated with 600 ml of saline solution and methylene blue;\n* 1\u002F3 of patients will undergo treatment with an intragastric balloon inflated with 700 ml of saline solution and methylene blue.\n\nAll balloons will remain in place for 6 months, as per the instructions provided in the product technical data sheet.\n\nAll the techniques described have already been widely validated by the scientific literature and are commonly used in bariatric endoscopy.\n\nSample size: assuming a significant level of 0.05, to detect as significant a medium effect size (f=0.25) with a power of 80% performing an ANOVA model we will need to enrol 156 patients (52 in each group). Taking into account a possible 5% of drop-out at the enrollment, the total number of patients will be around 165 (55 per group).\n\nINFORMED CONSENT: Will be obtained upon first registration of the patient in the computer archive, as required by the hospital computer system, for access to personal data, which will be then used anonymously.",[28],[352],"Intragastric balloon","2024-11-20",{"date":355,"type":36},"2024-11-22",{"date":357,"type":36},"2022-08-20",{"date":359,"type":20},"2025-06",{"name":361,"class":74},"Mater Olbia Hospital",{"id":363,"slug":364,"hasResults":11,"nctId":365,"briefTitle":366,"officialTitle":366,"acronym":4,"eligibilityCriteria":367,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":368,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":370,"conditions":371,"keywords":373,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":377,"lastUpdatePostDateStruct":378,"startDateStruct":380,"completionDateStruct":382,"leadSponsor":384,"locationsCount":75},"100561470","validity-and-reliability-of-the-6-minute-pegboard-ring-test-in-obese-individuals-100561470","NCT06590584","Validity and Reliability of the 6-minute Pegboard Ring Test in Obese Individuals","Inclusion Criteria:\n\n* BMI value of 30 kg\u002Fm2 and above,\n* Ability to ambulate,\n* Being 18 years of age and above,\n* Being a volunteer.\n\nExclusion Criteria:\n\n* Use of anti-obesity medication,\n* Pregnancy,\n* Latent autoimmune diabetes,\n* Chronic renal failure,\n* Active or serious infections,\n* Liver failure,\n* Recent major cardiovascular events,\n* Unstable angina,\n* Heart failure (NYHA III-IV)\n* Respiratory failure, cardiac arrhythmias, neoplastic diseases, and neurological or musculoskeletal disorders that limit testing.",{"count":369,"type":20},50,"Obesity is a major public health problem that causes numerous diseases and problems that threaten human health. The prevalence of obesity has increased worldwide in the last \\~50 years and has reached pandemic levels. Similar results are seen in Turkey, and according to the results of the Turkey Health Survey, 20.2% of people aged 15 and over were obese and 35.6% were pre-obese in 2022. Obesity represents a major health problem as it significantly increases the risk of diseases such as type 2 diabetes mellitus, fatty liver disease, hypertension, myocardial infarction, stroke, dementia, osteoarthritis, obstructive sleep apnea and various cancers, thus contributing to a decrease in both quality of life and life expectancy. Obesity is also associated with unemployment, social disadvantages and reduced socio-economic productivity, thus representing an increasing economic burden.\n\nObesity is associated with physiological changes at the muscle level, including a decrease in capillary density and blood flow, thus limiting the supply of oxygen and energy resources. Along with the limited blood flow, muscle cells in obese individuals have a decrease in the relative number and size of mitochondria required for energy supply. This leads to a limitation in upper limb activities.\n\nThis activity restriction is related to many activities of daily living that involve unsupported upper extremity movements that lead to dyspnea and fatigue in patients with cardiopulmonary disease. Therefore, determining the strength, endurance and exercise capacity of the upper extremities emerges as an important issue in obesity management. One of the tests that serve this purpose is the 6-minute pegboard ring test (6PBRT), which has been found to be valid and reliable in patients with chronic obstructive pulmonary disease and asthma. However, when the literature is examined, it is seen that 6PBRT has not been studied in obese individuals. Therefore, the aim of the study is to investigate the validity and reliability of 6PBRT in obese individuals.\n\nThe main question it aims to answer is:\n\n\\- Is 6PBRT a valid and reliable method to assess upper extremity functional capacity in patients wit obesity?",[28,27,372],"Obese",[95,374,375,376],"exercise test","upper extremity","arm exercise endurance","2024-09-09",{"date":379,"type":36},"2024-09-19",{"date":381,"type":36},"2024-08-01",{"date":383,"type":20},"2025-06-28",{"name":385,"class":74},"Selcuk University"]